a Department of Neurosurgery , Massachusetts General Hospital , Boston , MA , USA.
b Cancer Center, Department of Medicine , Massachusetts General Hospital , Boston , MA , USA.
Expert Rev Mol Diagn. 2017 Oct;17(10):943-947. doi: 10.1080/14737159.2017.1374854. Epub 2017 Sep 6.
Minimally invasive methods will augment the clinical approach for establishing the diagnosis or monitoring treatment response of central nervous system tumors. Liquid biopsy by blood or cerebrospinal fluid sampling holds promise in this regard. Areas covered: In this literature review, the authors highlight recent studies describing the analysis of circulating tumor cells, cell free nucleic acids, and extracellular vesicles as strategies to accomplish liquid biopsy in glioblastoma and metastatic tumors. The authors then discuss the continued efforts to improve signal detection, standardize the liquid biopsy handling and preparation, develop platforms for clinical application, and establish a role for liquid biopsies in personalized medicine. Expert commentary: As the technologies used to analyze these biomarkers continue to evolve, we propose that there is a future potential to precisely diagnose and monitor treatment response with liquid biopsies.
微创方法将增强中枢神经系统肿瘤的临床诊断或监测治疗反应的方法。通过血液或脑脊液取样的液体活检在这方面具有前景。
在这篇文献综述中，作者强调了最近描述分析循环肿瘤细胞、游离核酸和细胞外囊泡作为实现胶质母细胞瘤和转移性肿瘤液体活检的策略的研究。作者随后讨论了提高信号检测、标准化液体活检处理和准备、开发临床应用平台以及在个性化医疗中确立液体活检作用的持续努力。
随着用于分析这些生物标志物的技术不断发展，我们提出，液体活检具有精确诊断和监测治疗反应的未来潜力。
